Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.51 |
| ▸ | JAK2 | O60674 | 18/20 | 0.51 |
| ▸ | TYK2 | P29597 | 17/20 | 0.51 |
| ▸ | JAK3 | P52333 | 8/20 | 0.50 |
| ▸ | STAT3 | P40763 | 2/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16606006 | 0.92 | JAK2 (0.48) | JAK1JAK2TYK2JAK3KDR | |
| Hydrochloric Acid SCHEMBL16423487 | 0.91 | JAK2 (0.48) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL16423457 | 0.85 | TYK2 (0.48) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL16423514 | 0.85 | JAK1 (0.47) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL16424014 | 0.84 | JAK1 (0.54) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL16424198 | 0.82 | JAK1 (0.46) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL16606000 | 0.80 | TYK2 (0.50) | JAK1JAK2TYK2JAK3KDR | |
| Hydrochloric Acid SCHEMBL16423252 | 0.80 | TYK2 (0.49) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL16593959 | 0.78 | TYK2 (0.47) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL15336761 | 0.77 | KDR (0.46) | JAK1JAK2TYK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | JAK1 15/4885JAK2 14/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.